Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab

BACKGROUND: Long‐term management of moderate‐to‐severe psoriasis is usually discussed in terms of continuous administration; however, there are many situations in clinical practice where treatment may be withdrawn with subsequent retreatment. OBJECTIVE: To assess the clinical course after ixekizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Umezawa, Y., Torisu‐Itakura, H., Morisaki, Y., ElMaraghy, H., Nakajo, K., Akashi, N., Saeki, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587494/
https://www.ncbi.nlm.nih.gov/pubmed/30325534
http://dx.doi.org/10.1111/jdv.15292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587494/
https://www.ncbi.nlm.nih.gov/pubmed/30325534
http://dx.doi.org/10.1111/jdv.15292

Ejemplares similares